Effect Of Age On Outcome

Intuitively, older patients should do poorly following an allogeneic SCT. Most studies have shown that recipient age is an important prognostic factor for nonre-lapse mortality (NRM).11 In a majority of the large trials using a myeloablative regimen with related712-14 and unrelated donors,1215-17 this holds true. However, in one large study by Deeg et al.8 that used targeted busulfan levels in a myeloablative conditioning regimen, in a multivariate analysis, there was no significant effect of age (up to 66 years) on relapse-free survival (RFS). The data on the use of nonmyeloabative transplants for older patients is still evolving and could potentially improve the outcome of older patients undergoing an allogeneic SCT.

0 0

Post a comment